ArticlePloS one2026
Stage-specific associations of mineralization markers with CKM syndrome: Nationwide survey and genetic evidence for Alkaline phosphatase's unique clinical role.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular-Kidney-Metabolic (CKM) syndrome involves disordered mineralization processes. Herein, we investigated the serum alkaline phosphatase (ALP), calcium, and phosphorus across CKM stages.
methodsThis study analyzed 15,233 eligible participants in National Health and Nutrition Examination Survey (2009-2018) using survey-weighted multinomial logistic regression to assess associations of ALP, calcium, and phosphorus. Restricted cubic splines assessed non-linear relationships, while Cox models examined mortality risks. Two-sample Mendelian randomization (MR) explored causal relationships.
resultsRelative risk ratios (RRRs) and 95% confidence intervals (95% CI) were calculated with multinomial logistic regression. Compared with stage 0, ALP was positively associated with the likelihood of being classified into stage 2 (RRR, 1.23[95% CI, 1.11-1.37]), stage 3 (RRR, 1.99 [95% CI, 1.48-2.67]), stage 4a (RRR, 1.29 [95% CI, 1.14-1.46]), stage 4b (RRR, 1.35 [95% CI, 1.16-1.58]). Per mg/dL increase in serum calcium levels was associated with a higher likelihood of being classified into stages 2 (RRR = 2.13, 95% CI: 1.55-2.94) and CKM stage 4, while per mg/dL increase in serum phosphorus was associated with stage 3 classification (RRR = 2.85, 95% CI: 1.77-4.59) and the results remained consistent after standardizing the markers using z-scores. ALP's 4th quartile was associated with the highest mortality risks (CKM-cause hazard ratio = 2.20; all-cause hazard ratio = 2.15). MR analysis indicated potential causal effects of ALP on cardiovascular disease and of chronic kidney disease on ALP.
conclusionsALP demonstrates consistent associations with all CKM stages. These findings indicate that ALP-related mechanisms need further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.